Navigation Links
Access Highlighted in Recent BusinessWeek Article
Date:9/11/2007

DALLAS, Sept. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that renowned business columnist Gene Marcial of BusinessWeek, highlighted Access Pharmaceuticals in the most recent edition dated September 17, 2007. The article is also available on http://www.BusinessWeek.com under the 'Inside Wall Street' column.

The article focused upon the major opportunity Access' lead compound, ProLindac, has to offer shareholders. ProLindac, a platinum-based drug that is currently in Phase II clinical trials for ovarian and colorectal cancer, has the potential to be a next generation cancer therapy, which is currently dominated by Eloxatin, a current platinum drug that produces revenues in excess of $2 billion and is close to patent expiration in the U.S. Marcial also noted that Dr. Esteban Cvitkovic, Access' Vice-Chairman (Europe) and Senior Director, Oncology Clinical R&D, was responsible for developing Eloxatin during his tenure at Sanofi-Aventis. The article references certain products of Somanta Pharmaceuticals in the cancer area. While Access has executed a definitive merger agreement with Somanta, the acquisition has not yet closed and the closing is still subject to the satisfaction of the closing conditions set forth in the merger Agreement. The consummation of the acquisition is subject to numerous closing conditions.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. Access has announced the
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Research explains why women lack equal access to angel capital
2. Abbott vs. Thailand has implications for innovation and access
3. More access points for Madison wireless
4. GE partner allows real-time access to patient data
5. Broadband access needs a champion, FCC commissioner says
6. UW Trace center makes sending packages accessible to all
7. Green Bay area businesses ramp up wireless access
8. GE Healthcare, MobileAccess to collaborate on hospital wireless
9. Stem-cell debate, wireless access and other endeavors heat up
10. Computer access brings more Wisconsinites to libraries
11. Promega to get early access to WARF technologies under new agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
(Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
(Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... While radiation treatments deliver precise doses of high-energy ... to shrink tumors, oncologists have become increasingly concerned ... treatments to nerves responsible for upper body mobility. ... UC Davis Cancer Center researchers have taken the ...
... Department of Statistics and Centre for Complexity Science have ... the complex cell interactions that lead to cancer and ... such as Facebook for useful insights. An approach ... gain an understanding of a range of systems with ...
... As polar bears adapt to a warming Arctica frozen seascape ... unlikely source: snow goose eggs. New calculations show that changes ... nesting near the western Hudson Bay could provide at least ... new analysis appears in Polar Biology . "Over ...
Cached Biology News:UC Davis team refines cancer treatments to reduce potential nerve damage 2New tool could unpick complex cancer causes and help sociologists mine Facebook 2Goose eggs may help polar bears weather climate change 2
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: